AbbVie Invests $380 Million in Active Pharmaceutical Ingredient Manufacturing Expansion in North Chicago, Illinois

on

AbbVie announced a $380 million investment to build two active pharmaceutical ingredient (API) manufacturing facilities at its North Chicago, Illinois campus12

The new facilities will support production of next-generation neuroscience and obesity medications using advanced manufacturing technologies integrated with artificial intelligence2

Construction will begin in spring 2026, with both facilities expected to be fully operational in 202912

AbbVie plans to hire 300 people in North Chicago including engineers, scientists, manufacturing operators, and lab technicians12

This investment is part of AbbVie's $100 billion commitment to U.S. research and development and capital investments over the next decade2

The company has 10 neuroscience candidates in Phase 1 and 2 trials, making neuroscience a cornerstone of its pipeline, while its obesity pipeline is currently limited to a Phase 1 program1

In the past six months, AbbVie has committed $575 million to North Chicago, including a previously announced $195 million chemical synthesis facility that broke ground in September 20254

Sources:

1. https://www.biospace.com/business/abbvie-backs-obesity-push-with-380m-api-production-expansion-project-in-illinois

2. https://www.prnewswire.com/news-releases/abbvie-to-invest-380-million-in-north-chicago-to-further-expand-active-pharmaceutical-ingredient-manufacturing-in-the-united-states-302694659.html

4. https://patch.com/illinois/libertyville/abbvie-bring-300-new-jobs-through-380m-investment-new-pharmaceutical-plants